BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin. Lung Cancer 2012;78:92-9. [DOI: 10.1016/j.lungcan.2012.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Lan G, Lin L, Chen X, Chen L, Chen X. Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer. Med Sci Monit 2017;23:5683-9. [PMID: 29186089 DOI: 10.12659/msm.904836] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Morales-espinosa D, García-román S, Karachaliou N, Rosell R. Pharmacogenomics in the treatment of lung cancer: an update. Pharmacogenomics 2015;16:1751-60. [DOI: 10.2217/pgs.15.99] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
3 Bagley SJ, Vitale S, Zhang S, Aggarwal C, Evans TL, Alley EW, Cohen RB, Langer CJ, Blair IA, Vachani A, Whitehead AS. Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer. Clin Lung Cancer 2017;18:e143-9. [PMID: 27863923 DOI: 10.1016/j.cllc.2016.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Bai Y, Ma X, Zhang YH. Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients. J Chemother 2021;:1-11. [PMID: 34877924 DOI: 10.1080/1120009X.2021.2009989] [Reference Citation Analysis]
5 Ban EZ, Lye MS, Chong PP, Yap YY, Lim SYC, Abdul Rahman H. Association of hOGG1 Ser326Cys, ITGA2 C807T, TNF-A -308G>A and XPD Lys751Gln polymorphisms with the survival of Malaysian NPC patients. PLoS One 2018;13:e0198332. [PMID: 29912899 DOI: 10.1371/journal.pone.0198332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Pérez-ramírez C, Cañadas-garre M, Alnatsha A, Villar E, Delgado JR, Faus-dáder MJ, Calleja-hernández MŸ. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacological Research 2016;111:877-84. [DOI: 10.1016/j.phrs.2016.08.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
7 Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol 2016;77:5-18. [PMID: 26589793 DOI: 10.1007/s00280-015-2901-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
8 Woo HI, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. Pharmacogenomics 2015;16:383-91. [PMID: 25823786 DOI: 10.2217/pgs.15.14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer. 2013;133:1016-1022. [PMID: 23390054 DOI: 10.1002/ijc.28078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kucharczyk T, Krawczyk P, Powrózek T, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Knetki-Wróblewska M, Winiarczyk K, Krzakowski M, Milanowski J. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. Pathol Oncol Res 2016;22:49-56. [PMID: 26277606 DOI: 10.1007/s12253-015-9966-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Krawczyk P, Kucharczyk T, Kowalski DM, Powrózek T, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Knetki-Wróblewska M, Wojas-Krawczyk K, Kałakucka K, Dyszkiewicz W, Krzakowski M, Milanowski J. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol 2014;140:2047-57. [PMID: 25028118 DOI: 10.1007/s00432-014-1756-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
12 Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opinion on Drug Metabolism & Toxicology 2016;12:307-17. [DOI: 10.1517/17425255.2016.1141894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
13 Zhang N, Ouyang Y, Chang J, Liu P, Tian X, Yu J. Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis. Biomed Res Int 2020;2020:3520764. [PMID: 33150172 DOI: 10.1155/2020/3520764] [Reference Citation Analysis]
14 Pérez-ramírez C, Cañadas-garre M, Molina MÁ, Robles AI, Faus-dáder MJ, Calleja-hernández MÁ. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research/Reviews in Mutation Research 2017;771:32-58. [DOI: 10.1016/j.mrrev.2016.11.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
15 Liao WY, Ho CC, Tsai TH, Chen KY, Shih JY, Yu CJ. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer 2018;118:90-6. [PMID: 29572009 DOI: 10.1016/j.lungcan.2018.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol 2013;72:1125-32. [PMID: 24067998 DOI: 10.1007/s00280-013-2299-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
17 Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, Xu L. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8:e72251. [PMID: 23977265 DOI: 10.1371/journal.pone.0072251] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
18 Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer 2015;16:358-65. [DOI: 10.1016/j.cllc.2015.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
19 Zhang J, Xue ZQ, Wang B, Wen JX, Wang YX. Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer. Iran J Basic Med Sci 2020;23:329-36. [PMID: 32440319 DOI: 10.22038/IJBMS.2019.39291.9320] [Reference Citation Analysis]
20 Zhang G, Zeng R, Wang K, A Y, Li L, Gong K. Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis. Oncol Lett 2019;17:2874-80. [PMID: 30854063 DOI: 10.3892/ol.2019.9894] [Reference Citation Analysis]
21 Dediu M, Alexandru A, Bratu F. Pemetrexed in non-small-cell lung cancer. Lung Cancer Management 2014;3:273-85. [DOI: 10.2217/lmt.14.16] [Reference Citation Analysis]
22 Hoang PT, Ambroise J, Dekairelle AF, Durant JF, Butoescu V, Chi VL, Huynh N, Nguyen TB, Robert A, Vermylen C, Gala JL. Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? Br J Clin Pharmacol 2015;79:429-40. [PMID: 25099492 DOI: 10.1111/bcp.12481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, Pilotto S, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. Lung Cancer 2015;88:319-24. [PMID: 25870156 DOI: 10.1016/j.lungcan.2015.03.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
24 Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol 2014;9:1146-53. [PMID: 25157767 DOI: 10.1097/JTO.0000000000000217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
25 Ojha RP, Gurney JG. Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review. Leukemia & Lymphoma 2013;55:67-73. [DOI: 10.3109/10428194.2013.792336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
26 Han F, Xu W. Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis. Pteridines 2021;32:23-32. [DOI: 10.1515/pteridines-2020-0026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, Song X, Wang J, Jin L, Wu J, Li Q, Bai C, Han B, Gao Z, Lu D. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol 2014;35:11159-70. [PMID: 25104092 DOI: 10.1007/s13277-014-2427-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
28 Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Gannon J, Adjei AA, Adjei AA, Ramnath N. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. J Thorac Oncol 2014;9:222-30. [PMID: 24419420 DOI: 10.1097/JTO.0000000000000062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
29 Yan M, Wu J, Xue M, Mo J, Zheng L, Zhang J, Gao Z, Bao Y. The Studies of Prognostic Factors and the Genetic Polymorphism of Methylenetetrahydrofolate Reductase C667T in Thymic Epithelial Tumors. Front Oncol 2022;12:847957. [PMID: 35734597 DOI: 10.3389/fonc.2022.847957] [Reference Citation Analysis]
30 Corrigan A, Walker JL, Wickramasinghe S, Hernandez MA, Newhouse SJ, Folarin AA, Lewis CM, Sanderson JD, Spicer J, Marinaki AM. Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. Pharmacogenomics J 2014;14:411-7. [DOI: 10.1038/tpj.2014.13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
31 Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. Radiol Oncol 2014;48:163-72. [PMID: 24991206 DOI: 10.2478/raon-2013-0086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
32 Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Villar E, Valdivia-Bautista J, Faus-Dáder MJ, Calleja-Hernández MÁ. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J 2019;19:164-77. [PMID: 29662106 DOI: 10.1038/s41397-018-0014-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]